Skip to main content

Yes Bank FPO shares to list on July 27; stock plunges 49% in 2 weeks

The price band was Rs 12-13 and the share price was Rs 30.45 on June 10. Hence, the correction till around its issue price was on expected lines.

Shares allotted in the follow-on public offer of Yes Bank will list on the bourses on July 27.

The private sector lender raised Rs 14,272 crore through its latest FPO which was subscribed 95 percent during July 15-17.

The issue size was Rs 15,000 crore, so the balance amount would have be contributed by its issue underwriter SBI Capital Markets. In the issue prospectus, SBI Capital Markets committed underwriting amount of up to Rs 3,000 crore.

The final issue price has been fixed at Rs 12 per share, the lower end of the price band of Rs 12-13. Employees received shares at Re 1 discount to issue price.

FPO shares were allotted to eligible participants in the issue on July 23 and the same shares were credited to their accounts on July 24.


"Securities of Yes Bank are listed and admitted for trading on the exchange with effect from July 27, 2020. These shares rank pari-passu with the existing equity shares of the company," said the BSE in its release.

Yes Bank, which raised Rs 4,098 crore through anchor book and rest through the issue during July 15-17, was subscribed 93 percent while including anchor book, the subscription stood at 95 percent largely supported by QIB category which saw subscription of 1.90 times.

State Bank of India is the largest shareholder in Yes Bank with 48.21 percent stake followed by ICICI Bank, HDFC, Axis Bank, Kotak Mahindra Bank, Bandhan Bank, Federal Bank and IDFC First Bank, which all invested Rs 10,000 crore in Yes Bank under Reconstruction Scheme in March this year.

Yes Bank share price has been corrected consistently since July 10, losing 48.8 percent to close at Rs 13.65 on July 24. It shed 55 percent since the announcement of FPO price band on June 10.

The price band was Rs 12-13 and the share price was Rs 30.45 on June 10. Hence, the correction till around its issue price was on expected lines.

Source - Moneycontrol.com

 


Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more